Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Myriad advances cancer diagnostic

This article was originally published in The Gray Sheet

Executive Summary

Myriad Genetics introduces the BRACAnalysis Rearrangement DNA sequencing assay Aug. 1 for prediction of breast and ovarian cancer in high-risk women. The molecular test, which is the first commercially available to detect rare "large rearrangement" genetic mutations, will be used as an adjunct for "exceptionally" high-risk women who test negative with Myriad's already available BRACAnalysis test. A study published in the Journal of the American Medical Association in March signaled the need for such a test to help identify cancer-predisposing genes in up to 12% of high-risk women testing negative with Myriad's broader assay (1"The Gray Sheet" March 27, 2006, p. 15)...

You may also be interested in...

Myriad Genetics Says It Will Fill Gap In Cancer Risk Prediction

Myriad Genetics plans to release an advanced predict-tive genetic test for breast and ovarian cancer later this year, in line with study recommendations put forth in the Journal of the American Medical Association

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts